Second-degree atrioventricular block Medical Services in China

Second-degree atrioventricular (AV) block is a cardiac conduction disorder characterized by intermittent failure of electrical impulses to propagate from the atria to the ventricles. It is classified into two main types: Mobitz Type I (Wenckebach), where PR intervals progressively lengthen until a P wave fails to conduct, and Mobitz Type II, marked by sudden non-conducted P waves without preceding PR prolongation—often indicating more serious infra-Hisian disease. Symptoms range from asymptomatic findings on routine ECG to dizziness, syncope, fatigue, or presyncope, particularly with high-grade or advanced forms. Diagnosis relies on 12-lead ECG, Holter monitoring, and sometimes electrophysiological studies to localize the level of block and assess risk for progression to complete heart block. Management depends on type, symptoms, and underlying etiology: asymptomatic Mobitz Type I may require only observation, whereas Mobitz Type II or symptomatic cases typically necessitate permanent pacemaker implantation.

China offers distinct advantages for international patients seeking treatment: cardiovascular specialists at tier-1 hospitals (e.g., Fu Wai Hospital, Shanghai Ruijin) possess extensive experience in complex arrhythmia management and device-based therapies, including MRI-compatible and leadless pacemakers. Advanced imaging (3T cardiac MRI, high-density electroanatomic mapping) and robotic-assisted implantation enhance procedural precision and long-term outcomes. Clinical success rates for pacemaker implantation exceed 99%, with low complication incidence and robust post-implant follow-up protocols. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality—comprehensive packages include diagnostics, surgery, hospital stay, and device fees. As a dedicated medical tourism agency, we facilitate seamless access: vetting accredited hospitals, coordinating appointments with bilingual cardiologists, providing transparent all-inclusive pricing, arranging visas and local logistics, and offering dedicated care coordinators throughout the patient journey—from pre-travel consultation to post-discharge telehealth support.

Treatment Options & Itemized Cost Breakdown: Second-Degree Atrioventricular Block (Cardiology Department)

Non-Surgical / Conservative Management

*Indicated for asymptomatic Mobitz I (Wenckebach), stable hemodynamics, no structural heart disease, and reversible causes (e.g., drug-induced, electrolyte imbalance).*

• •Electrolyte correction & medication adjustment: $45–$120 (IV potassium/magnesium infusion + ECG monitoring × 24h; drug discontinuation protocol)
• •Ambulatory ECG monitoring (72-h Holter): $85–$135
• •Baseline labs: $65 (serum K⁺, Mg²⁺, Ca²⁺, creatinine, TSH, troponin I)
• •Echocardiogram (TTE): $140–$210
• •Follow-up outpatient visits (3-month cycle): $35–$55/visit

Surgical / Procedural Intervention

*Indicated for symptomatic Mobitz II, advanced AV block, wide QRS complex, or progression on Holter.*

• •Preoperative workup: $290–$410

- Cardiac MRI (if suspected infiltrative disease): $380 - Electrophysiology study (EPS): $420–$650

• •Permanent dual-chamber pacemaker implantation (DDD): $4,800–$7,200

• •Leadless pacemaker (Micra AV): $12,500–$15,800

Special/Complex Condition Management

• •Acute myocardial infarction–associated Mobitz II: Urgent revascularization + temporary pacing → permanent pacing: $8,900–$13,400 total (PCI + pacemaker)
• •Lyme carditis–related block: IV ceftriaxone × 14 days ($220) + observation; pacing only if persistent: $5,100–$7,500
• •Post-cardiac surgery AV block: Temporary epicardial pacing ($380/day) + delayed permanent implant at 7–14 days: $5,300–$7,800

Quick Selection Guide

• •Asymptomatic elderly (>75 y), low budget, no comorbidities: Conservative monitoring — total 3-month cost: $280–$420
• •Symptomatic Mobitz II, age 45–65, no renal/hepatic disease: Standard DDD pacemaker — $5,100–$7,600 (optimal balance of efficacy, durability, cost)
• •Young athlete with Lyme seropositivity & transient block: Antibiotics + Holter surveillance — $320–$490, avoid device unless recurrent
• •High-bleeding-risk patient (e.g., anticoagulated AF, CKD stage 4): Leadless pacemaker — $12,800–$16,100, eliminates lead-related complications
• •Acute STEMI + new Mobitz II: Immediate PCI + urgent pacing — $9,200–$13,900, prioritizes ischemia resolution first